Rotavirus is the leading cause of severe diarrhea among children worldwide. Children are immunized against rotavirus by either GlaxoSmithKline plc's (GSK) Rotarix or Merck & Co. Inc.'s (MRK) RotaTeq, both of which are oral vaccines.
Rotavac, a new rotavirus vaccine developed in India, has demonstrated its efficacy in preventing severe rotavirus diarrhea in a phase III clinical trial that enrolled 6,799 infants.
The vaccine developed by the Government of India's Department of Biotechnology and Bharat Biotech significantly reduced severe rotavirus diarrhea by 56 percent during the first year of life, with protection continuing into the second year of life, according to the trial results. The vaccine also showed impact against severe diarrhea of any cause.
Bharat Biotech intends to file for registration of Rotavac in India. The vaccine, which is likely to be priced at $1.00, may be a more affordable alternative to the rotavirus vaccines already on the market, says the company.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.